14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NMTC vs STEX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, NeuroOne Medical Technologies Corporation (NMTC) is the stronger overall head-to-head candidate over Streamex Corp. (STEX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas STEX carries 51.3/100 (HOLD) at $0.33 (N/M Forward P/E, -36966.7% operating margin).
Composite vs. Pillar Nuance: While STEX currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. NMTC 45.5/100 HOLD), NMTC captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-63.4% vs. -36966.7% operating margin) and revenue trajectory (+16.3% vs. +0.0% YoY).
Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile STEX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Capital Markets value chain with $56.2M market capitalization and -36966.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NMTC vs STEX Key Questions & Quantitative Answers
As of Nov 20, 2026, NeuroOne Medical Technologies Corporation (NMTC) is the stronger overall head-to-head candidate over Streamex Corp. (STEX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas STEX carries 51.3/100 (HOLD) at $0.33 (N/M Forward P/E, -36966.7% operating margin). Composite vs. Pillar Nuance: While STEX currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. NMTC 45.5/100 HOLD), NMTC captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-63.4% vs. -36966.7% operating margin) and revenue trajectory (+16.3% vs. +0.0% YoY). Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile STEX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NMTC leads the Growth & Scale pillar: NMTC posts +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin), compared with STEX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $291,000 TTM revenue (100.0% gross margin, -36966.7% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), NMTC cumulative revenue shifted N/A while STEX shifted N/A. In operating R&D and SG&A reinvestment, NMTC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STEX.
NMTC screens cheaper on headline valuation multiples. NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin), whereas STEX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMTC (-124.7% ROE) versus STEX (-775.2% ROE) capital efficiency.
In options market volatility and institutional positioning, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk). By comparison, STEX carries 423.6% implied volatility (61st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.71β · 127% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.